Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 58


Recent Progress in the Prevention of Serogroup B Meningococcal Disease.

Feavers IM, Maiden MCJ.

Clin Vaccine Immunol. 2017 May 5;24(5). pii: e00566-16. doi: 10.1128/CVI.00566-16. Print 2017 May. Review.


Meningococcal serogroup B vaccines: Estimating breadth of coverage.

Donald RG, Hawkins JC, Hao L, Liberator P, Jones TR, Harris SL, Perez JL, Eiden JJ, Jansen KU, Anderson AS.

Hum Vaccin Immunother. 2017 Feb;13(2):255-265. doi: 10.1080/21645515.2017.1264750. Epub 2016 Dec 14.


Serum Bactericidal Antibody Responses of Adults Immunized with the MenB-4C Vaccine against Genetically Diverse Serogroup B Meningococci.

Giuntini S, Lujan E, Gibani MM, Dold C, Rollier CS, Pollard AJ, Granoff DM.

Clin Vaccine Immunol. 2017 Jan 5;24(1). pii: e00430-16. doi: 10.1128/CVI.00430-16. Print 2017 Jan.


Meningococcal Factor H Binding Protein Vaccine Antigens with Increased Thermal Stability and Decreased Binding of Human Factor H.

Rossi R, Konar M, Beernink PT.

Infect Immun. 2016 May 24;84(6):1735-42. doi: 10.1128/IAI.01491-15. Print 2016 Jun.


Expression of factor H binding protein in meningococcal strains can vary at least 15-fold and is genetically determined.

Biagini M, Spinsanti M, De Angelis G, Tomei S, Ferlenghi I, Scarselli M, Rigat F, Messuti N, Biolchi A, Muzzi A, Anderloni G, Brunelli B, Cartocci E, Buricchi F, Tani C, Stella M, Moschioni M, Del Tordello E, Colaprico A, Savino S, Giuliani MM, Delany I, Pizza M, Costantino P, Norais N, Rappuoli R, Masignani V.

Proc Natl Acad Sci U S A. 2016 Mar 8;113(10):2714-9. doi: 10.1073/pnas.1521142113. Epub 2016 Feb 17.


Immunogenicity, Safety, and Tolerability of Bivalent rLP2086 Meningococcal Group B Vaccine Administered Concomitantly With Diphtheria, Tetanus, and Acellular Pertussis and Inactivated Poliomyelitis Vaccines to Healthy Adolescents.

Vesikari T, Wysocki J, Beeslaar J, Eiden J, Jiang Q, Jansen KU, Jones TR, Harris SL, O'Neill RE, York LJ, Perez JL.

J Pediatric Infect Dis Soc. 2016 Jun;5(2):180-7. doi: 10.1093/jpids/piv064. Epub 2016 Jan 23.


Meningococcal B vaccination strategies and their practical application in Italy.

Gasparini R, Amicizia D, Lai PL, Panatto D.

J Prev Med Hyg. 2015 Aug 31;56(3):E133-9. Review.


A meningococcal vaccine antigen engineered to increase thermal stability and stabilize protective epitopes.

Konar M, Pajon R, Beernink PT.

Proc Natl Acad Sci U S A. 2015 Dec 1;112(48):14823-8. doi: 10.1073/pnas.1507829112. Epub 2015 Nov 16.


Effect of complement Factor H on anti-FHbp serum bactericidal antibody responses of infant rhesus macaques boosted with a licensed meningococcal serogroup B vaccine.

Giuntini S, Beernink PT, Granoff DM.

Vaccine. 2015 Dec 16;33(51):7168-75. doi: 10.1016/j.vaccine.2015.10.135. Epub 2015 Nov 10.


Susceptibility of Meningococcal Strains Responsible for Two Serogroup B Outbreaks on U.S. University Campuses to Serum Bactericidal Activity Elicited by the MenB-4C Vaccine.

Rossi R, Beernink PT, Giuntini S, Granoff DM.

Clin Vaccine Immunol. 2015 Dec;22(12):1227-34. doi: 10.1128/CVI.00474-15. Epub 2015 Sep 30.


Meningococcal Serogroup B Bivalent rLP2086 Vaccine Elicits Broad and Robust Serum Bactericidal Responses in Healthy Adolescents.

Vesikari T, Østergaard L, Diez-Domingo J, Wysocki J, Flodmark CE, Beeslaar J, Eiden J, Jiang Q, Jansen KU, Jones TR, Harris SL, O'Neill RE, York LJ, Crowther G, Perez JL.

J Pediatric Infect Dis Soc. 2016 Jun;5(2):152-60. doi: 10.1093/jpids/piv039. Epub 2015 Aug 4.


Optimization of Molecular Approaches to Genogroup Neisseria meningitidis Carriage Isolates and Implications for Monitoring the Impact of New Serogroup B Vaccines.

Rojas E, Hoyos J, Oldfield NJ, Lee P, Flint M, Jones CH, Ala'Aldeen DA, Jansen KU, Anderson AS.

PLoS One. 2015 Jul 6;10(7):e0132140. doi: 10.1371/journal.pone.0132140. eCollection 2015.


Binding of Complement Factor H (FH) Decreases Protective Anti-FH Binding Protein Antibody Responses of Infant Rhesus Macaques Immunized With a Meningococcal Serogroup B Vaccine.

Granoff DM, Costa I, Konar M, Giuntini S, Van Rompay KK, Beernink PT.

J Infect Dis. 2015 Sep 1;212(5):784-92. doi: 10.1093/infdis/jiv081. Epub 2015 Feb 12.


Binding of complement factor H to PorB3 and NspA enhances resistance of Neisseria meningitidis to anti-factor H binding protein bactericidal activity.

Giuntini S, Pajon R, Ram S, Granoff DM.

Infect Immun. 2015 Apr;83(4):1536-45. doi: 10.1128/IAI.02984-14. Epub 2015 Feb 2.


Neisseria meningitidis porA, fetA and fHbp gene distribution in Western Australia 2000 to 2011.

Boan P, Metasan N, Tempone S, Harnett G, Speers DJ, Keil AD.

BMC Infect Dis. 2014 Dec 12;14:686. doi: 10.1186/s12879-014-0686-x.


The discovery and development of a novel vaccine to protect against Neisseria meningitidis Serogroup B Disease.

Zlotnick GW, Jones TR, Liberator P, Hao L, Harris S, McNeil LK, Zhu D, Perez J, Eiden J, Jansen KU, Anderson AS.

Hum Vaccin Immunother. 2015;11(1):5-13. doi: 10.4161/hv.34293. Epub 2014 Nov 1. Review.


Genetic diversity and levels of expression of factor H binding protein among carriage isolates of Neisseria meningitidis.

Lemée L, Hong E, Etienne M, Deghmane AE, Delbos V, Terrade A, Berthelot G, Caron F, Taha MK.

PLoS One. 2014 Sep 23;9(9):e107240. doi: 10.1371/journal.pone.0107240. eCollection 2014.


Human factor H (FH) impairs protective meningococcal anti-FHbp antibody responses and the antibodies enhance FH binding.

Costa I, Pajon R, Granoff DM.

MBio. 2014 Aug 26;5(5):e01625-14. doi: 10.1128/mBio.01625-14.


New versus old meningococcal group B vaccines: how the new ones may benefit infants & toddlers.

Panatto D, Amicizia D, Lai PL, Cristina ML, Domnich A, Gasparini R.

Indian J Med Res. 2013 Dec;138(6):835-46. Review.

Supplemental Content

Support Center